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Technologies to develop new metal medicinesUnderstanding the mechanism of action of anti-cancer
agents is of paramount importance for drug develop-
ment. NMR spectroscopy can provide insights into the
kinetics and thermodynamics of the binding of metal-
lodrugs to biomolecules. NMR is most sensitive for
highly abundant I = 1/2 nuclei with large magnetic
moments. Polarization transfer can enhance NMR sig-
nals of insensitive nuclei at physiologically-relevant
concentrations. This paper reviews NMR methods
for speciation of precious metal anti-cancer complexes,
including platinum-group and gold-based anti-cancer
agents. Examples of NMR studies involving interactions
with DNA and proteins in particular are highlighted.
Introduction
The successful clinical application of cisplatin and its second
(carboplatin) and third (oxaliplatin) generation derivatives to
treat cancers has greatly stimulated interest in metal-based
anti-cancer agents. Many precious metal (Ru, Rh, Os, Ir, Pt
and Au) coordination complexes are now showing promising
anti-tumor activity [1,2]. Understanding the thermodynamic
stability of metal complexes and the kinetics of their reac-
tions with biomolecules is crucial for elucidating their mech-
anisms of action. Both the ligand and metal ion can play
important roles in the anti-cancer effects. Nuclear magnetic*Corresponding author.: P.J. Sadler (P.J.Sadler@warwick.ac.uk)
1740-6749/$  2015 The Authors. Published by Elsevier Ltd. All rights reserved. http://dx.dSection editor:
Francois M.U. Dufrasne, Universite´ Libre de Bruxelles,
Brussels, Belgium.
resonance (NMR) spectroscopy, the absorption of electro-
magnetic radiation by magnetic nuclei, is a powerful method
for speciation of metal complexes in solution and in biologi-
cal systems. NMR spectroscopy can often be used to deter-
mine not only the structures of molecules (ca. <30 kDa) in
solution, but also the strength of metal binding to biomole-
cules (equilibrium constants, including DNA and proteins)
and kinetics of dynamic processes (including rates of ligand
exchange on a microsecond to second timescale). This review
summarizes the application of NMR methods to speciation in
biological systems, with a focus on platinum-group and gold-
based anti-cancer complexes in solution.
NMR sensitivity
In principle, NMR signals can be detected for all isotopes that
have non-zero nuclear spins (i.e., an odd number of neutrons
or protons in their nuclei). The spin (I)-1/2 nuclei (e.g., 1H,
13C, 15N, 19F, 31P, 195Pt) are the most widely studied. The
I > 1/2 nuclei (quadruplar nuclei) are less useful in practical
NMR applications due to their broad NMR signals caused by
rapid quadrupolar relaxation, with the exception of sym-
metrical environments [3]. Unfortunately, 75% stable
magnetic nuclides have I > 1/2. For platinum-group and
gold metals, nuclei of interest are 195Pt (natural abundanceoi.org/10.1016/j.ddtec.2015.08.002 7
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Table 1. NMR responsive ligand nuclei and metal ion nuclei.
Isotope Abundance
(%)
Nuclear
spin (I)
Magnetogyric
ratio (g, 107 rad/Ts)
Relative
sensitivity
(1H = 1.00)
Quadruple
moment
(1028*Q/m2)
Chemical shift
range (ppm)
1H 99.98 1/2 26.7519 1.00 0 +20 to 50
2H 1.5  102 1 4.1066 9.65  106 0.0028 +12 to 25
3H 0 1/2 28.535 1.21 0 +12 to 25
6Li 7.42 1 3.9371 8.5  103 0.0008 +3 to 9
7Li 92.58 3/2 10.3976 0.29 0.04 +3 to 10
10B 19.58 3 2.875 1.99  102 8.5  102 +100 to 100
11B 80.42 3/2 8.584 0.17 4.1  102 +100 to 120
13C 1.108 1/2 6.7283 1.59  102 0 +250 to 25
14N 99.635 1 1.9338 1.01  103 0.0199 +800 to 400
15N 0.365 1/2 2.712 1.04  103 0 +620 to 420
17O 3.7  102 5/2 3.6279 3.7  102 3.6279 +1600 to 50
19F 100 1/2 25.181 0.83 0 +900 to 500
23Na 100 3/2 7.0801 9.25  102 0.1 +20 to 70
29Si 4.7 1/2 5.3188 7.84  103 0 +270 to 580
31P 100 1/2 10.841 6.63  102 0 +1400 to 500
33S 0.76 3/2 2.055 2.26  103 0.055 +400 to 600
35Cl 75.53 3/2 2.624 4.7  103 0.1 +1000 to 200
37Cl 24.47 3/2 2.1842 2.71  103 0.079 +1000 to 200
79Br 50.54 3/2 6.7228 7.86  102 0.37 –
81Br 49.46 3/2 7.2468 9.85  102 0.31 –
99Ru 12.72 3/2 1.234 1.95  104 0.076 +8000 to 1000
100Ru 17.07 5/2 1.383 1.41  103 0.44 –
103Rh 100 1/2 0.846 3.11  105 0 +10 000 to 2000
105Pd 22.2 5/2 1.2305 0.65 +8000 to 1000
127I 100 5/2 5.3817 9.34  102 0.79 –
187Os 1.64 1/2 0.616 1.22  105 0 –
189Os 16.1 3/2 0.8475 2.34  103 0.8 –
191Ir 37.3 3/2 0.4643 2.53  105 1.1 –
193Ir 62.7 3/2 0.5054 3.27  105 1.0 –
195Pt 33.7 1/2 5.768 9.94  103 0 +11 840 to 3000
197Au 100 3/2 0.4625 2.51  105 0.59 –
Source: http://www.bruker-nmr.de/guide/eNMR/chem/NMRnuclei.html; http://www-usr.rider.edu/grushow/nmr/NMR_tutor/periodic_table/.of 33.7%), 187Os (1.64%) and 103Rh (100%) with I = 1/2, but
their sensitivity is not high (especially 187Os and 103Rh).
NMR signal intensity is proportional to B0
2g3 (B0 is magnetic
field, g is magnetogyric ratio), while the signal-to-noise ratio
is proportional to B0
3/2g5/2. Taking 195Pt as an example,
g(195Pt) is 4.6-fold lower than g(1H), and hence the relative
intensity of 195Pt is 100 times lower than that of 1H. 187Os
and 103Rh nuclei are even less sensitive due to much lower
magnetogyric ratios. Table 1 lists some NMR parameters of
ligand and metal nuclei of interest for NMR studies in bio-
logical systems.8 www.drugdiscoverytoday.comPolarization transfer methods, such as DEPT (Distortion-
less Enhancement by Polarization Transfer), can enhance
NMR sensitivity for low magnetogyric ratio nuclei [4,5].
INEPT (Insensitive Nuclei Enhanced by Polarization Transfer)
can enhance signal intensities by transferring nuclear spin
polarization from sensitive spins (I, usually 1H) to the less
sensitive nucleus (S) [5]. The sensitivity can be increased by a
factor of g(I)/g(S) through INEPT. Heteronuclear Single-Quan-
tum Correlation spectroscopy (HSQC) utilizes INEPT to trans-
fer the magnetization from 1H to a nearby heteronucleus
linked through one bond, resulting in 2D NMR spectra (e.g.
Vol. 16, 2015 Drug Discovery Today: Technologies | Technologies to develop new metal medicines[1H,13C] HSQC, [1H,15N] HSQC). Heteronuclear Multiple-
Quantum Correlation spectra (HMQC) are almost identical
to HSQC spectra. However, there are few metal complexes in
which 1H is directly bound to a metal. In other cases, Hetero-
nuclear Multiple-Bond Correlation spectroscopy (HMBC) can
be helpful, since it is possible to detect nuclei coupled to more
distant protons. HMBC utilizes long-range coupling to 1H
nuclei, usually through 2–4 bonds.
NMR studies of precious metal complexes in biological
systems
The speciation of metal complexes can be investigated by
NMR through either ligand nuclei or metal nuclei. Among
the platinum group and gold nuclei, only 195Pt has a reason-
able sensitivity for NMR (relative sensitivity compared to 1H
9.94  103). Therefore, the speciation of these metal com-
plexes is mostly focused on ligand nuclei. Another issue is the
paramagnetic effect, which leads to shifts and broadening of
NMR signals. Thus, the oxidation state of the metal should be
considered if sharp NMR signals are anticipated.
Ruthenium
Ru(III) (low-spin 4d5) complexes, such as the anti-metastatic
drug NAMI-A (H2Im[trans-RuCl4(DMSO)HIm], HIm = 1H-im-
idazole) and anti-cancer KP1019 [H2ind][trans-RuCl4(Hind)2]
(Hind = 1H-indazole), are paramagnetic; however, their para-
magnetic NMR spectra are still obtainable and useful for study-
ing their transformation in biological environments. The 1H
NMR spectrum of trans-[RuCl4(Him)2]
 in D2O (Fig. 1A) in D2O
shows three broad peaks (d = 5.87, 15.83 and 21.25 ppm)
assignable to coordinated imidazole [6]. A stepwise exchange
of Cl by D2O is observed over a period of 16.6 hours at 310 K.
Ru(III) polycarboxylates have been used to treat septic shock
caused by bacteria-induced NO formation. These complexes
react readily with NO to form [RuNO] species with reduction of
RuIII to RuII and oxidation of NO to NO+, forming stable Ru–NO
bonds. Reaction of [RuII(hedta)] (hedta3 = N-(hydroxyethy-
l)ethylenediaminetriacetate) with NO gives an 15N NMR peak
for [RuII(hedta)(15NO+)] d(15N) at 249.6 ppm (Fig. 1B), while
the two-electron reduction product [RuII(hedta)(15NO)]2 is a
mixture of cis- and trans-equatorial isomers, d(15N) at 609.4 and
607.4 ppm [7].
NMR can distinguish stereoisomers of octahedral Ru(II)
complexes. Xie et al. have combined double quantum-filtered
correlation spectroscopy (DQF-COSY), HSQC, HMBC and
NOESY experiments to study the stereochemistry of Ru(II)
polypyridyl complexes (Fig. 1C) and fully assigned the NMR
signals of enantiomers [8]. A unique binding mode between
the anticancer complex [(h6-biphenyl)Ru(en)Cl]+ and DNA
with Ru(II) coordinated to N7 of guanine and concomitant p-
stacking intercalation of the non-coordinated phenyl group
into nearby base pairs has been characterized by NMR (Table
2, entries 1 and 2) [9]. The analogous complex, [(h6-tha)Ru(en)Cl]+ (tha = tetrahydroanthracene), also exhibits com-
bined coordinative bonding and intercalation [10].
Rhodium
103Rh is highly abundant (100%) with I = 1/2, but has a very
low magnetogyric ratio (Table 1). The 103Rh NMR chemical
shifts of [(COD)RhI(Phosphine)X] complexes, recorded using
inverse 2D [1H,103Rh] and [31P,103Rh]{1H} NMR, range from
+557 to –332 ppm [11]. Dirhodium(II) acetate complexes are
spin-paired and diamagnetic. 2D NMR studies by Dunbar et al.
revealed an intrastrand binding between cis-[Rh2(m-
O2CCH3)2(h
1-O2CCH3)]
+ and DNA (Table 2, entry 3) [12].
The binding of the two Rh centers to C5 and A6 results in
significant disruption of H-bonds between base pairs and
hence destabilizes the DNA duplex. They also reported an
interesting binding mode of cis-[Rh2(dap)(m-O2CCH3)2(h
1-
O2CCH3)(CH3OH)](O2CCH3)]
+ (dap = 1,12-diazaperylene)
binding with a DNA oligonucleotide (Table 2, entry 4) [13].
NMR studies indicated binding between one Rh and N7 of
adenine and a cooperative intercalative binding via the dap
ligand (on the other Rh center) stacking with the same ade-
nine. The octahedral rhodium(III) complexes developed by
Barton and coworkers can specifically recognize mismatched
DNA. The binding interactions of the D-[Rh(bpy)2chrysi]
3+
(chrysi = 5,6-chrysenequinonediimine) with CC mismatched
DNA oligomers have been studied by NMR (Table 2, entry 5)
[14]. NOESY and COSY experiments indicate a deep insertion
into a minor grove site of CC mismatched DNA and such
binding does not significantly alter the conformation of DNA.
Osmium
187Os also has I = 1/2, but NMR observation is hampered by its
low natural abundance (1.61%) and small magnetogyric
ratio. Bell et al. have studied [Os(arene)X2L] complexes using
inverse [1H,187Os] and [31P,187Os]{1H} NMR. There is a large
d(187Os) range from –1697 to –5265 ppm [15]. Meanwhile, the
effects of ligand electronic properties and steric effects on
d(187Os) have been separately compared by variation of arene,
halide and phosphine ligands. Gray et al. have reported the
[1H,187Os] HMBC spectrum of [Os(h6-biphenyl)2](OTf)2 com-
plex (Fig. 1D) [16]. Interestingly, coupling between all the
protons and 187Os was detected, except for H8 which is the
furthest away. Fu et al. studied hydrolysis and DNA binding of
anti-cancer OsII complexes [Os(h6-arene)(XY)Z]PF6 (are-
ne = p-cymene, XY = Impy-NMe2, and Z = Cl) by
1H NMR
[17]. The OsII complex undergoes hydrolysis to 99% extent
after incubation at 310 K for 24 hours. The aqua adduct can
bind to 9-EtG, as revealed by the downfield shift of 1H
resonances of the OsII ligand and upfield shift of 9-EtG H8.
More importantly, the aqua adduct can oxidize NADH to
NAD+ catalytically via forming a hydride adduct with a 1H
signal at –4.2 ppm.www.drugdiscoverytoday.com 9
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Figure 1. (a) Stepwise hydrolysis of trans-[RuCl4(Him)2]
, a Ru(III) complex closely related to KP1019. (b) Structures of [RuII(hedta)(15NO+)] and
[RuII(hedta)(15NO)]2. (c) Stereoisomers of Ru(II) polypyridyl complexes. (d) Structure of [Os(h6-biphenyl)2]
2+ and its [1H,187Os] HMBC spectrum
(25 mM in d4-MeOD at 500 MHz for 1H). Adapted with permission [15]. Copyright  2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
(e) Hydrolysis of [(h5-Cp*)Ir(ppy)Cl] and [(h5-Cp*)Ir(bpy)Cl]+ under physiological conditions.
10 www.drugdiscoverytoday.com
Vol. 16, 2015 Drug Discovery Today: Technologies | Technologies to develop new metal medicines
Table 2. Examples of recent NMR studies on metal complex–nucleic acid interactions.
Entry Compound DNA oligomers NMR Results Reference
1 50-ATACATGGTACATA-30
30-TATGTACCATGTAT-50
NOESY Unique binding mode. Ru
selective for G N7;
uncoordinated phenyl ring
intercalates into nearby
base pairs.
[9]
2 50-CGGCCG-30
50-GCCGGC-30
[1H, 1H] ROESY, NOESY
[1H, 15N] HSQC [1H, 31P]
Binding mode similar to
[(h6-biphenyl)Ru(en)Cl]+.
Binds to G3 and G6 by Ru,
intercalation of arene rings.
[10]
3 50-CTCTCAACT TCC-30
30-GAGAGTTGAAGG-50
DQF-COSY NOESY
[1H,13C] HSQC
Intrastrand adduct; two Rh
centers bind to N4 of C5
and N7 of A6 in major
groves. Destabilizes duplex
DNA (DTm = 22.9 8C),
weakens base stacking and
disrupts H-bonding within
the base pairs.
[12]
4 50-CCTTCAACTCTC-30
30-GGAAGTTGAGAG-50
DQF-COSY NOESY Rh binds to N7 of A6; the
planar p-conjugated N^N
ligand at the other Rh forms
p-stacking interactions with
the same A ligand. No
significant bending of the
aromatic group.
[13]
5 50-CGGACTCCG-30
30-GCCTCAGGC-50
NOESY, COSY, 31P NMR Bulky chrysi ligand
selectively inserts into CC
mismatched site in minor
grove with ejection of
mismatched CC to opposite
major groove; 31P NMR
suggests opening of
phosphate groups at CC
mismatched site to allow
space for bulky ligand. No
distortion of DNA
[14]
6 50-ATATGTACATAT-30
30-TATTCATGTATA-50
[1H,15N] HSQC 1H NMR
31P NMR
Kinetics and mechanism;
binding of polyamine.
Formation of
monofunctional adduct with
BBR3007 is 3.5-fold faster
than BBR3464; BBR3007
and BBR3610 form several
conformers with DNA;
BBR3464 forms only two
conformers.
[23]
www.drugdiscoverytoday.com 11
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Table 2 (Continued )
Entry Compound DNA oligomers NMR Results Reference
7 50-CGCGAATTCGCG-30
30-CGGCTTAAGCGC-50
50-CGTACG-30
30-GCATGC-50
COSY, TOCSY NOESY
HSQC HMQC 31P NMR
Phosphate clamp binding
mode: H-bond between
ammines on Pt complex and
phosphate oxygens. Middle
Pt moiety mainly contacts
A6, T7 and T8, two terminal
Pt moieties interact with
C9G10 of both strands.
[24]
8 50-CCTCGTCC-30
30-GGAGCAGG-50
COSY TOCSY NOESY Dual metallation/
intercalation combined 2D
NMR and restrained
molecular dynamics/
molecular mechanics. Pt
coordinates to N7 of
guanine in major groove;
ACRAMTU intercalates
into nearby base pairs;
duplex DNA stabilized.
[25]Iridium
Iridium(III) complexes are often considered to be inert in
biological systems, but have recently gained increasing at-
tention as anti-cancer agents. Cusanelli et al. determined the
rate constant for exchange of H2O on [Ir(H2O)6]
3+ to be
1.1  1010 s1 (300 years residence time) by 17O NMR
[18]. However, if Cp* (h5-pentamethylcyclopentadienyl an-
ion) is introduced, the hydrolysis (often a key step to activate
cytotoxicity in cancer cells) rate is significantly accelerated
[19]. For example, the 1H NMR experiments indicate that
both [(h5-Cp*)Ir(bpy)Cl]+ (bpy = 2,20-biphenyl) and [(h5-
Cp*)Ir(ppy)Cl] (Hppy = 2-phenylpyridine) (Fig. 1E) can un-
dergo rapid hydrolysis (minutes) [20,21]. Surprisingly, the
cytotoxicity of [(h5-Cp*)Ir(ppy)Cl] (IC50 = 10.8 mM) is signifi-
cantly higher than [(h5-Cp*)Ir(bpy)Cl]+ (IC50 > 100 mM).
1H
NMR experiments reveal that both complexes form adducts
with 9-EtG, but [(h5-Cp*)Ir(ppy)Cl] also binds to adenine. 2D
1H–1H TOCSY and NOESY NMR further show that the latter
complex binds to adenine at N1. The higher lipophilicity
(hence higher cellular uptake) and stronger binding with
nucleobases may account for the higher cytotoxicity [21].
Notably, the transfer of hydride from NADH to [(h5-Cpxbi-
ph
)Ir
III(ppy)Cl] (Cpxbiph = biphenyltetramethylcyclopentadie-
nyl) to give [(h5-Cpxbiph)IrIII(phpy)(H)] is clear from the high-
field-shifted Ir–H 1H NMR peak, d(1H) = –14.7 ppm [22].
Platinum and gold
Platinum complexes are the most widely investigated metal-
based anti-cancer agents. 195Pt (I = 1/2, 33.7% abundance) is
useful to study interactions with biomolecules. For example, in
the hydrolysis of a Pt(IV) prodrug containing axial haloacetato12 www.drugdiscoverytoday.comligands under physiological conditions, the 195Pt NMR peak for
[Pt(dach)(tfa)2(ox)] (dach = cyclohexane-1,2-diamine, tfa = -
trifluoroacetate, ox = oxalato) shifts from +1625 ppm to
+1425 ppm in monohydroxido [Pt(dach)(tfa)(OH)(ox)] and
+1310 ppm in dihydroxido [Pt(dach)(OH)2(ox)] (Fig. 2A)
[26]. The kinetics of binding of Pt complexes to nucleobases
can be determined by 195Pt NMR [27]. Bancroft et al. compared
the kinetics of reactions of cisplatin and transplatin with DNA.
Rate constants for forming monofunctional adducts follow
pseudo-first-order kinetics with k = (10.2  0.7)  105 s1 for
cisplatin and k = (9.6  0.4)  105 for transplatin at pH 6.5
and 37 8C (d(195Pt)  2300 ppm for both monocomplexes).
The rate constant for loss of monofunctional adducts (to form
bifunctional adducts) for cisplatin k = (9.2  1.4)  105 s1 is
higher than that for transplatin with k = (6.3  0.7)  105 s1
[27]. The pKa values of Pt aqua complexes can be determined by
NMR. For example, the pKa of trans-[PtCl(H2O)(
15NH3)(c-
C6H11
15NH2)] was determined to be 5.4 by
195Pt NMR, and
values for two isomers of cis-[PtCl(H2O)(
15NH3)(c-
C6H11
15NH2)] were the same (6.73) by [
1H,15N] HSQC NMR [28].
For cisplatin and its derivatives, the trans-influence of L in
15N–195Pt–L strongly influences both the 15N chemical shift
and 195Pt–15N coupling constant (lJ(195Pt–15N; see Fig. 2B)
[29–31]. For example, the binding of cis-[PtCl2(
15NH3)2] to
the protein kinase Mnk1 or apoMnk1 leads to a significant
change in 15N shift. As shown in the [1H,15N] HSQC NMR
spectra (Fig. 2C, a–c), d(15N) of 15N-labeled cisplatin at
67 ppm shifts to 66 and 83 ppm for the mono-aqua
species [32]. After 3-hours incubation with apoMnk1, new
peaks with d(15N) of 66 and 38 ppm appeared, correspond-
ing to cis-[PtCl(15NH3)2Scys] species. Further incubation for
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Figure 2. (a) Hydrolysis of Pt(IV) complex [Pt(dach)(tfa)2(ox)]. (b) Left: range of d(
1H) and d(15N) in NH3–Pt
II and NH3–Pt
IV with different trans-ligands.
Right: range of d(1H) and d(15N) in NH3–Pt
II, NH2–Pt
II, NH–PtII with different trans-ligands. Adapted with permission [31]. Copyright  1996 Published by
Elsevier B.V. (c) Binding of cis-[(PtCl)2](
15NH3)2 to protein kinase. [
1H,15N] HSQC spectra of cis-PtCl2(
15NH3)2 mixed with equimolar ratio of (a–c)
apoMnk1 and (d–f) Cu+–Mnk1 at 0 hours (a and d), 3 hours (b and e), and 24 hours (c and f). Reproduced with permission [32]. Copyright  2014 Wiley-
VCH Verlag GmbH & Co. KGaA, Weinheim. (d) 3D structure of [PtCl(en)(ACRAMTU-S)]2+ binding to DNA oligonucleotide. Redrawn from PDB 1XRW
[25].
www.drugdiscoverytoday.com 13
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to {Pt(15NH3)2} binding to two cysteine residues. The [
1H,15N]
HSQC NMR experiments with Cu+-Mnk1 similarly show the
binding of cis-{Pt(15NH3)2} species to cysteine residues of the
protein, suggestive of replacement of Cu+ by cis-
{Pt(15NH3)2}
2+ (Fig. 2C, d–f). Such results were confirmed
by [1H,13C] HSQC experiments for the mixture of 15N,13C-
Cys labeled kinase with cisplatin [32]. A similar interaction
was identified by [1H,15N] HSQC NMR for cisplatin with 15N-
labeled Cu chaperone Atox1 [33]. Besides binding to cysteine
thiols, Pt drugs can also bind to methionine sulfur (leading to
a S chiral center) before reaching their DNA target. The
binding of [Pt(dien)Cl]+ (dien = diethylenetriamine) to Met
studied by [1H,15N] HSQC NMR showed an interchange
between S- and N-bound Met. Lowing the pH to 3 resulted
in the ring-opened product [Pt(dienH-N,N0)(L-Met-S,N)],
where the existence of two chiral centers at S and Ca of
Met gives rise to four diastereomers [34].
[1H,15N] 2D HSQC NMR is useful in the study of
non-covalent binding. Ruhayel et al. investigated poly-
amine-DNA interactions through [1H,15N] 2D HSQC NMR
(Table 2, entry 6) [23]. The replacement of the central Pt-
tetraam(m)ine unit in [{trans-PtCl(NH3)2}2(m-trans-Pt-
(NH3)2{NH2(CH2)6NH2}2)]
4+ (BBR3464) by an amine
(BBR3007) or ethylendiamine (BBR3610) unit shows several
binding conformers while BBR3464 only has two discrete
conformers, which is a possible reason for the more potent
cytotoxicity of the latter two complexes than BBR3464. Qu
et al. studied phosphate clamp binding of TriplatinNC to a
DNA oligonucleotide (Table 2, entry 7) [24]. Significant
changes in 1H,15N chemical shifts and 1J(195Pt-15N) cou-
plings indicated formation of H-bonds between ammine
of Pt complexes and phosphate oxygens.
The 3D NMR structure of [PtCl(en)(ACRAMTU-S)]2+
(ACRAMTU = 1-[2-(acridin-9-ylamino)ethyl]-1,3-
dimethylthiourea) bound to a DNA oligonucleotide (together
with restrained molecular dynamics/molecular mechanics)
indicates a dual metalation of N7 of guanine and an interca-
lation of the acridine moiety into neighboring base pairs
(Table 2, entry 6 and Fig. 2D) [25]. Multinuclear NMR experi-
ments on the photo-induced Pt(IV) to Pt(II) activation of
cis,trans,cis-[PtIV(N3)2(OH)2(NH3)2] in the presence of 1-
methylimidazole (1-MeIm) showed photo-isomerization
and trans-labilisation products, accompanied by release of
N3
, ammonia, and formation of O2 under 365 nm UVA
irradiation [35].
Owing to the extremely low magnetogyric ratio and large
quadruple moment of 197Au, NMR studies on gold complexes
are focused only on ligand nuclei. Ligand exchange reactions
of [AuI(NHC)2]
+ (NHC = N-heterocyclic carbene) with cyste-
ine/selenocysteine [36], Au(III) reduction to Au(I) [37], and
binding interactions of gold(I) complexes with model pep-
tides [38] have been investigated by 1H NMR.14 www.drugdiscoverytoday.comOther NMR methods
NMR can be applied to more complicated systems such as
biofluids, including use of high resolution magic angle spin-
ning (HR-MAS) to sharpen broad peaks and study metabolite
profiling [39], and drug delivery systems [40]. HR-MAS is
commonly used in solid state NMR (ssNMR) to study poly-
mers, nanoparticles and supramolecular systems [41]. Nota-
bly, paramagnetic effects can be useful and have practical
applications. Paramagnetic gadolinium-based magnetic reso-
nance imaging (MRI) contrast agents have been widely used
for body imaging by shortening the relaxation times of 1H in
H2O which interacts with contrast agents. NMR can be cou-
pled with HPLC and mass spectrometry; the combined
HPLC-1H NMR-MS detection is a powerful method to study
complicated mixtures of for example, metabolites in human
urine, by continuous flow [42].
Conclusion
NMR spectroscopy is making important contributions to
understanding the molecular mechanisms of action of an-
ti-cancer metal complexes by providing valuable insights into
their chemical speciation in biological systems. The sensitiv-
ity of nuclei to detection is a key concern for NMR character-
ization and currently most NMR studies are based on ligand
rather than metal nuclei. The sensitivity of metal nuclei (as
well as other heteronuclei) can often be enhanced by isotope
enrichment and polarization transfer methods. Representa-
tive examples of NMR studies on precious metal complexes
interacting with biomolecules (e.g., DNA, proteins) highlight
the powerful potential of NMR spectroscopy for studying, not
only the structures, but also the thermodynamics and kinet-
ics of chemical speciation of therapeutic metal complexes in
biological systems.
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